You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 20, 2024

Details for Patent: 9,220,694

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,220,694 protect, and when does it expire?

Patent 9,220,694 protects VERKAZIA and is included in one NDA.

This patent has forty-four patent family members in eighteen countries.

Summary for Patent: 9,220,694

Title:	Emulsion compositions containing cetalkonium chloride
Abstract:	Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
Inventor(s):	Rabinovich-Guilatt; Laura (Kadima, IL), Lambert; Gregory (Chatenay Malabry, FR), Lallemand; Frederic (Fresnes, FR), Philips; Betty (Antony, FR)
Assignee:	SANTEN SAS (Evry, FR)
Application Number:	13/957,621
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Process; Device;

Drugs Protected by US Patent 9,220,694

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	VERKAZIA	cyclosporine	EMULSION;OPHTHALMIC	214965-001	Jun 23, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,220,694

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	06291236	Jul 28, 2006
	07112097	Jul 9, 2007
	PCT/IB2007/053441	Jul 10, 2007

International Family Members for US Patent 9,220,694

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007278141	⤷ Try a Trial
Canada	2659322	⤷ Try a Trial
China	101534791	⤷ Try a Trial
Cyprus	1114457	⤷ Try a Trial
Cyprus	1118148	⤷ Try a Trial
Cyprus	1118436	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.